The Relapsed/Refractory Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Relapsed/Refractory Acute Myeloid Leukemia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Relapsed/Refractory Acute Myeloid Leukemia Market.
Some of the key takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report:
Companies across the globe are diligently working toward developing novel Relapsed/Refractory Acute Myeloid Leukemia treatment therapies with a considerable amount of success over the years.
Relapsed/Refractory Acute Myeloid Leukemia companies working in the treatment market are Cellectis, Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi, TC Biopharm, Merck & Co, GlycoMimetics, AROG Pharmaceuticals, Ascentage Pharma Group Inc., Advesya SAS, Technische Universität Dresden, Molecular Partners AG, Hui Zeng, Shanxi Bethune Hospital, Chongqing Precision Biotech, UNC Lineberger Comprehensive, AB Science, Chongqing Precision Biotech, Aptose Biosciences Inc., Wake Forest University Health Sciences, Actinium Pharmaceuticals, Delta-Fly Pharma, Ryvu Therapeutics SA, Guangzhou Bio-gene Tech, Tarapeutics Science Inc., GlycoMimetics Incorporated, TC Biopharm, Vor Biopharma, Sumitomo Pharma America, Hutchmed, and others, are developing therapies for the Relapsed/Refractory Acute Myeloid Leukemia treatment
Emerging Relapsed/Refractory Acute Myeloid Leukemia therapies in the different phases of clinical trials are- UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, APG-2575, CCTx-001, Venetoclax Oral Tablet, MP0533, Mitoxantrone liposome, Selinexor, CD123 CAR-T cells, pembrolizumab, AB8939, CD123 CAR-T cells, Tuspetinib, CPI 613, MRX2843, DFP-10917, RVU120, G1805, HYML-122, Uproleselan, TCB008, VCAR33, DSP-5336, HMPL-306 Regimen, and others are expected to have a significant impact on the Relapsed/Refractory Acute Myeloid Leukemia market in the coming years.
In May 2024, GlycoMimetics, a biotechnology company based in the United States, has unveiled the top-line findings from its Phase III clinical trial involving uproleselan, an E-selectin antagonist tailored for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML). The study, which is randomized, double-blind, and placebo-controlled, has been investigating the efficacy of uproleselan in combination with either mitoxantrone, etoposide, and cytarabine (MEC) or fludarabine, cytarabine, and idarubicin (FAI) chemotherapy regimens. Patients were administered either uproleselan or a placebo during one cycle of induction and up to three cycles of consolidation, if applicable.
In January 2024, SELLAS Life Sciences Group, Inc. has disclosed that SLS009 (formerly known as GFH009) has received fast track designation from the FDA for potential utilization as a therapeutic remedy in patients grappling with relapsed or refractory acute myeloid leukemia (AML). The safety and effectiveness of this CDK9 inhibitor, when combined with venetoclax (Venclexta) and azacitidine (Vidaza), are under investigation in an ongoing phase 1/2 trial (NCT04588922) involving this patient cohort.
Relapsed/Refractory Acute Myeloid Leukemia Overview
The relapsed/refractory acute myeloid leukemia (AML) pipeline refers to the collection of investigational drugs and therapies that are currently being developed to treat AML patients who have experienced relapse or have not responded to standard treatments. This pipeline includes various drug candidates at different stages of clinical development, ranging from early-phase trials to late-stage clinical trials.
Get a Free Sample PDF Report to know more about Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight
Emerging Relapsed/Refractory Acute Myeloid Leukemia Drugs Under Different Phases of Clinical Development Include:
UCART 123: Cellectis
FHD-286: Foghorn Therapeutics
AB8939: AB Science
ONC201: Oncoceutics
Sarclisa: Sanofi
TCB008: TC Biopharm
Keytruda: Merck & Co
Uproleselan: GlycoMimetics
Crenolanib: AROG Pharmaceuticals
Relapsed/Refractory Acute Myeloid Leukemia Route of Administration
Relapsed/Refractory Acute Myeloid Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Relapsed/Refractory Acute Myeloid Leukemia Molecule Type
Relapsed/Refractory Acute Myeloid Leukemia Products have been categorized under various Molecule types, such as
Oligonucleotide
Peptide
Small molecule
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics Assessment
Relapsed/Refractory Acute Myeloid Leukemia Assessment by Product Type
Relapsed/Refractory Acute Myeloid Leukemia By Stage and Product Type
Relapsed/Refractory Acute Myeloid Leukemia Assessment by Route of Administration
Relapsed/Refractory Acute Myeloid Leukemia By Stage and Route of Administration
Relapsed/Refractory Acute Myeloid Leukemia Assessment by Molecule Type
Relapsed/Refractory Acute Myeloid Leukemia by Stage and Molecule Type
DelveInsight’s Relapsed/Refractory Acute Myeloid Leukemia Report covers around 75+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Relapsed/Refractory Acute Myeloid Leukemia product details are provided in the report. Download the Relapsed/Refractory Acute Myeloid Leukemia pipeline report to learn more about the emerging Relapsed/Refractory Acute Myeloid Leukemia therapies
Some of the key companies in the Relapsed/Refractory Acute Myeloid Leukemia Therapeutics Market include:
Key companies developing therapies for Relapsed/Refractory Acute Myeloid Leukemia are – Maxinovel Pty., Ltd., Cellectis S.A., Amgen, Ascentage Pharma, Shijiazhuang Yiling Pharmaceutical, CicloMed LLC, AB Science, Betta Pharmaceuticals Co., Ltd., Chongqing Precision Biotech Co., Ltd, Astellas Pharma, Keystone Nano, Cullinan Oncology, LLC, Arog Pharmaceuticals, Inc., GlycoMimetics Incorporated, Kite Pharma, Celyad Oncology SA, Novartis, PersonGen Biotherapeutics, Merck Sharp & Dohme LLC, Astex Pharmaceuticals, Mabwell (Shanghai) Bioscience Co., Ltd., Syndax Pharmaceuticals, Meryx, Inc., Cleave Therapeutics, Aptose Biosciences Inc., New Epsilon Innovation Limited, Guangdong Ruishun Biotech Co., Ltd, Hoffmann-La Roche, Prelude Therapeutics, Lava Therapeutics, and others.
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis:
The Relapsed/Refractory Acute Myeloid Leukemia pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Relapsed/Refractory Acute Myeloid Leukemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsed/Refractory Acute Myeloid Leukemia Treatment.
Relapsed/Refractory Acute Myeloid Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Relapsed/Refractory Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsed/Refractory Acute Myeloid Leukemia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Relapsed/Refractory Acute Myeloid Leukemia drugs and therapies
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Market Drivers
Rising incidence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, rising geriatric population are some of the important factors that are fueling the Relapsed/Refractory Acute Myeloid Leukemia Market.
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Market Barriers
However, high cost associated with the management of AML, side effects associated with the AML treatment and other factors are creating obstacles in the Relapsed/Refractory Acute Myeloid Leukemia Market growth.
Scope of Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drug Insight
Coverage: Global
Key Relapsed/Refractory Acute Myeloid Leukemia Companies: Cellectis, Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi, TC Biopharm, Merck & Co, GlycoMimetics, AROG Pharmaceuticals, Ascentage Pharma Group Inc., Advesya SAS, Technische Universität Dresden, Molecular Partners AG, Hui Zeng, Shanxi Bethune Hospital, Chongqing Precision Biotech, UNC Lineberger Comprehensive, AB Science, Chongqing Precision Biotech, Aptose Biosciences Inc., Wake Forest University Health Sciences, Actinium Pharmaceuticals, Delta-Fly Pharma, Ryvu Therapeutics SA, Guangzhou Bio-gene Tech, Tarapeutics Science Inc., GlycoMimetics Incorporated, TC Biopharm, Vor Biopharma, Sumitomo Pharma America, Hutchmed, and others
Key Relapsed/Refractory Acute Myeloid Leukemia Therapies: UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, APG-2575, CCTx-001, Venetoclax Oral Tablet, MP0533, Mitoxantrone liposome, Selinexor, CD123 CAR-T cells, pembrolizumab, AB8939, CD123 CAR-T cells, Tuspetinib, CPI 613, MRX2843, DFP-10917, RVU120, G1805, HYML-122, Uproleselan, TCB008, VCAR33, DSP-5336, HMPL-306 Regimen, and others
Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment: Relapsed/Refractory Acute Myeloid Leukemia current marketed and Relapsed/Refractory Acute Myeloid Leukemia emerging therapies
Relapsed/Refractory Acute Myeloid Leukemia Market Dynamics: Relapsed/Refractory Acute Myeloid Leukemia market drivers and Relapsed/Refractory Acute Myeloid Leukemia market barriers
Request for Sample PDF Report for Relapsed/Refractory Acute Myeloid Leukemia Pipeline Assessment and clinical trials
Table of Contents
1. Relapsed/Refractory Acute Myeloid Leukemia Report Introduction
2. Relapsed/Refractory Acute Myeloid Leukemia Executive Summary
3. Relapsed/Refractory Acute Myeloid Leukemia Overview
4. Relapsed/Refractory Acute Myeloid Leukemia- Analytical Perspective In-depth Commercial Assessment
5. Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics
6. Relapsed/Refractory Acute Myeloid Leukemia Late Stage Products (Phase II/III)
7. Relapsed/Refractory Acute Myeloid Leukemia Mid Stage Products (Phase II)
8. Relapsed/Refractory Acute Myeloid Leukemia Early Stage Products (Phase I)
9. Relapsed/Refractory Acute Myeloid Leukemia Preclinical Stage Products
10. Relapsed/Refractory Acute Myeloid Leukemia Therapeutics Assessment
11. Relapsed/Refractory Acute Myeloid Leukemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Relapsed/Refractory Acute Myeloid Leukemia Key Companies
14. Relapsed/Refractory Acute Myeloid Leukemia Key Products
15. Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs
16 . Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers
17. Relapsed/Refractory Acute Myeloid Leukemia Future Perspectives and Conclusion
18. Relapsed/Refractory Acute Myeloid Leukemia Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
